What is it about?
Safety and biomarkers of efficacy in a group of Alzheimer's disease patients treated with resveratrol versus placebo for 12 months.
Featured Image
Why is it important?
Treatments for Alzheimer's disease are unsatisfactory, and better treatments are needed.
Perspectives
This is the longest, largest highest dose trial of resveratrol completed to date in man. We found resveratrol to be save in high doses, and demonstrated evidence of efficacy. The findings warrant a follow-on Phase 3 study to test efficacy in a larger cohort.
Dr. Raymond Scott Turner
Georgetown University
Read the Original
This page is a summary of: Resveratrol for Alzheimer's disease, Annals of the New York Academy of Sciences, August 2017, Wiley,
DOI: 10.1111/nyas.13431.
You can read the full text:
Contributors
The following have contributed to this page
